Terms: = Lung cancer AND TRRAP, TR-AP, 8295, ENSG00000196367, Q9Y4A5, PAF400, PAF350/400, FLJ10671, STAF40, Tra1 AND Clinical Outcome
18 results:
1. Circulating cytokines associated with clinical outcomes in advanced non-small cell lung cancer patients who received chemoimmunotherapy.
Shi Y; Liu X; Du J; Zhang D; Liu J; Chen M; Zhao J; Zhong W; Xu Y; Wang M
Thorac Cancer; 2022 Jan; 13(2):219-227. PubMed ID: 34825500
[TBL] [Abstract] [Full Text] [Related]
2. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract] [Full Text] [Related]
3. Prognostic Significance of Patient-Reported outcomes in cancer.
Kerrigan K; Patel SB; Haaland B; Ose D; Weinberg Chalmers A; Haydell T; Meropol NJ; Akerley W
JCO Oncol Pract; 2020 Apr; 16(4):e313-e323. PubMed ID: 32048943
[TBL] [Abstract] [Full Text] [Related]
4. The efficacy and safety of zoledronic acid and strontium-89 in treating non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials.
Hu Z; Tian Y; Li W; Ruan Y; Zeng F
Support Care Cancer; 2020 Jul; 28(7):3291-3301. PubMed ID: 31754835
[TBL] [Abstract] [Full Text] [Related]
5. Erlotinib-Valproic Acid Liquisolid Formulation: Evaluating Oral Bioavailability and Cytotoxicity in Erlotinib-Resistant Non-small Cell lung cancer Cells.
Patel K; Doddapaneni R; Patki M; Sekar V; Bagde A; Singh M
AAPS PharmSciTech; 2019 Mar; 20(3):135. PubMed ID: 30830506
[TBL] [Abstract] [Full Text] [Related]
6. Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular Testing.
Schrock AB; Frampton GM; Herndon D; Greenbowe JR; Wang K; Lipson D; Yelensky R; Chalmers ZR; Chmielecki J; Elvin JA; Wollner M; Dvir A; -Gutman LS; Bordoni R; Peled N; Braiteh F; Raez L; Erlich R; Ou SH; Mohamed M; Ross JS; Stephens PJ; Ali SM; Miller VA
Clin Cancer Res; 2016 Jul; 22(13):3281-5. PubMed ID: 26933124
[TBL] [Abstract] [Full Text] [Related]
7. Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma.
Tsao AS; Liu S; Fujimoto J; Wistuba II; Lee JJ; Marom EM; Charnsangavej C; Fossella FV; Tran HT; Blumenschein GR; Papadimitrakopoulou V; Kies MS; Hong WK; Stewart DJ
J Thorac Oncol; 2011 Dec; 6(12):2104-11. PubMed ID: 21892101
[TBL] [Abstract] [Full Text] [Related]
8. Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324.
Blumenschein GR; Paulus R; Curran WJ; Robert F; Fossella F; Werner-Wasik M; Herbst RS; Doescher PO; Choy H; Komaki R
J Clin Oncol; 2011 Jun; 29(17):2312-8. PubMed ID: 21555682
[TBL] [Abstract] [Full Text] [Related]
9. Plasma biomarkers correlating with clinical outcome in a phase II study of sorafenib in advanced NSCLC.
Blumenschein GR; Reck M; Fossella F; Stewart DJ; Lathia C; Peña C
Cancer Biomark; 2011-2012; 10(6):287-98. PubMed ID: 22820084
[TBL] [Abstract] [Full Text] [Related]
10. [clinical features of hypersensitivity reactions to oxaliplatin among Chinese colorectal cancer patients].
Zhao Y; An X; Xiang XJ; Feng F; Wang FH; Wang ZQ; Xu RH; He YJ; Li YH
Chin J Cancer; 2010 Jan; 29(1):102-5. PubMed ID: 20038320
[TBL] [Abstract] [Full Text] [Related]
11. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
[TBL] [Abstract] [Full Text] [Related]
12. Effect of concomitant use of pentoxifylline and alpha-tocopherol with radiotherapy on the clinical outcome of patients with stage IIIB non-small cell lung cancer: a randomized prospective clinical trial.
Misirlioglu CH; Erkal H; Elgin Y; Ugur I; Altundag K
Med Oncol; 2006; 23(2):185-9. PubMed ID: 16720918
[TBL] [Abstract] [Full Text] [Related]
13. [A case of metastatic gastrointestinal stromal tumor developing a resistance to STI571 (imatinib mesylate)].
Miyake M; Takeda Y; Hasuike Y; Kashiwazaki M; Mishima H; Ikenaga M; Mano M; Takada Y; Hirota S; Tsujinaka T
Gan To Kagaku Ryoho; 2004 Oct; 31(11):1791-4. PubMed ID: 15553717
[TBL] [Abstract] [Full Text] [Related]
14. [Two head and neck cancer patients who responded to chemotherapy consisting of only TS-1].
Mikami Y; Tsukuda M; Kawai S; Kagesato Y; Tanigaki Y; Horiuchi C; Mochimatsu I
Gan To Kagaku Ryoho; 2003 Oct; 30(10):1473-7. PubMed ID: 14584280
[TBL] [Abstract] [Full Text] [Related]
15. The diagnostic value of pretreatment serum LDH in patients with limited disease small-cell lung carcinoma.
Stokkel MP; Van Eck-Smit BL; Zwinderman AH; Willems LN; Pauwels EK
Int J Biol Markers; 1997; 12(4):162-7. PubMed ID: 9582606
[TBL] [Abstract] [Full Text] [Related]
16. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.
Kleinerman ES
Hematol Oncol Clin North Am; 1995 Aug; 9(4):927-38. PubMed ID: 7490249
[TBL] [Abstract] [Full Text] [Related]
17. Localized benign and malignant fibrous tumors of the pleura. A clinicopathologic review of 223 cases.
England DM; Hochholzer L; McCarthy MJ
Am J Surg Pathol; 1989 Aug; 13(8):640-58. PubMed ID: 2665534
[TBL] [Abstract] [Full Text] [Related]
18. Morphometric and morphologic evaluations in stage III non-small cell lung cancers. Prognostic significance of quantitative assessment of infiltrating lymphoid cells.
Lee TK; Horner RD; Silverman JF; Chen YH; Jenny C; Scarantino CW
Cancer; 1989 Jan; 63(2):309-16. PubMed ID: 2535956
[TBL] [Abstract] [Full Text] [Related]
